香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 主席 常兆華博士 中國上海，二零二六年三月十九日 於本公告日期，本公司之執行董事為常兆華博士；本公司之非執行董事為谷峰博士、門慶兵博士及 孫維琴女士；及本公司之獨立非執行董事為周嘉鴻先生、劉國恩博士及邵春陽先生。 （股份代號：00853） 董事會會議召開日期 微創醫療科學有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事會」）兹通告謹定於二零二六年 三月三十一日（星期二）舉行董事會會議，藉以（其中包括）考慮及通過本集團截至二零二五年十二月 三十一日止年度的全年業績，以及處理其他事項。 承董事會命 微創醫療科學有限公司* 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） * 僅供識別 ...

文 章来源 ： 思 宇Me dTec h 转载要求：可以直接转载，请在文首注明来源 2026年3月18日， 微创 ® 集团宣布：不到一个月内 ， 2款创新介入器械 先后获得美国FDA突破性医疗器械认定 （Breakthrough Device Designation）。产品分 别来自 心脉医疗 和 微创脑科学 ，对应两个长期存在显著临床缺口的疾病治疗场景： 两款产品存在 3个共同特征： # 为什么思宇MedTech特别关注这件事？ 从医疗器械监管与产业趋势的角度看，此次"双入选"是值得注意的信号。 1. 入选比例极低 FDA突破性医疗器械项目自2015年设立以来，入选产品以欧美企业为主，中国介入类器械获得该认定的累计占比 不足1% 。同一集团短期内实现两项入选， 据思宇观察这是国内唯一，在全球行业里都较为罕见。 2. 将进入"加速通道"，缩短进入美国市场的时间周期 获得突破性认定后，产品在研发与注册阶段可获得三项关键支持： 但需要明确：认定不等于获批上市。 两款产品后续仍需完成FDA要求的关键临床试验并提交上市前审批申请（PMA）。（但一般获得认定的产品，上市成功 率确实高很多。） # 两个"全球空白"适应证 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額 ...

Core Viewpoint - The approval of the FireSpear™/火锋™ piezoelectric intravascular ultrasound treatment system marks a significant advancement in the treatment of chronic total occlusion (CTO) in coronary arteries, indicating a new exploration step for domestic companies in this complex disease area [2][17]. Group 1: Product Introduction - The FireSpear™/火锋™ system utilizes controlled mechanical vibrations to create directional impact forces, effectively breaking through fibrous caps and calcified lesions without damaging surrounding healthy vascular tissue, thus enhancing the success rate and efficiency of CTO procedures [11][12]. - This system is the first to apply piezoelectric effect principles in a coronary guidewire system, developed through a collaboration between 微创® 冠脉 and a team led by Academician Ge Junbo from Fudan University [11][12]. Group 2: CTO Technology Evolution - CTO is characterized by complete vascular occlusion lasting over three months, often seen as the "last fortress" in percutaneous coronary intervention (PCI) due to the complexity of the lesions [5][8]. - The evolution of CTO intervention has shifted from experience-based to evidence-based approaches, with recent studies and technological advancements paving the way for a more patient-centered and symptom-directed treatment paradigm [14][18]. Group 3: Industry Signals - The approval of the FireSpear™/火锋™ system signals a shift in domestic coronary device innovation towards high-difficulty segments, moving from mere replacement to path innovation in complex lesions [18]. - The diversification of energy-assisted technologies is emerging as a crucial variable in addressing complex PCI challenges, indicating a new direction for future innovations [19][20]. - The acceleration of high-end device localization is supported by policy and expedited review processes, although the long-term market structure will depend on clinical validation and practical experiences [21][22].

Core Viewpoint - Southbound funds reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 134,100 shares on February 27, while experiencing a net increase of 1,689,600 shares over the last five trading days [1] Group 1: Southbound Fund Activity - Over the past 20 trading days, MicroPort has seen 14 days of net increases from southbound funds, totaling 14,702,200 shares [1] - Currently, southbound funds hold 926 million shares of MicroPort, representing 48.28% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Core Viewpoint - MicroPort Medical (00853) reported HeartCare Medical (688016.SH) 2025 annual performance forecast, showing total revenue of approximately 1.351 billion yuan, a year-on-year increase of 11.96%, and a net profit attributable to the parent company of approximately 563 million yuan, a year-on-year increase of 12.17% [1] Group 1: Financial Performance - Total revenue for the year is approximately 1.351 billion yuan, reflecting a year-on-year growth of 11.96% [1] - Net profit attributable to the parent company is approximately 563 million yuan, with a year-on-year increase of 12.17% [1] - Basic earnings per share stand at 4.65 yuan [1] Group 2: Market Strategy and Sales - The company has strengthened its domestic leading position through strategies such as market penetration, customized treatment solutions, and product upgrades, leading to a steady increase in market share [1] - Overseas sales revenue exceeded 250 million yuan, representing a growth of over 55%, contributing to more than 18% of total revenue [1] - The company is actively promoting its products in Europe, Latin America, and Asia-Pacific, with sales coverage extending to 49 countries and regions [1] Group 3: Product Development and Approvals - Multiple innovative products have been approved for launch in China, including the Cratos branched aortic stent graft system and other medical kits [2] - A total of 23 products have received NMPA registration, and 11 products have been registered in 28 overseas markets [2] - The company has a rich pipeline of products under development, with several products entering various stages of clinical trials and regulatory submissions [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 1 股東及投資者請注意，以上財務資料根據中國會計準則編製，並僅與心脈醫療科技的業務有關，而 與本集團其他附屬公司無關。該等資料未經審核，且(a)並未撇除集團內交易，(b)並不包括本集團所 有業務，及(c)並不代表或全面反映本集團業務或狀況。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 微創醫療科學有限公司* 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月未經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的未經審核財務資料。本公司持有心脈醫療科技40.32%的股權，其業績於本公 司財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至 | 截至 | | | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 海外監管公告 常兆華博士 主席 本海外監管公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.10B條刊 發。 請參閱隨附上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）於上海證券交易所科創板 （「科創板」）刊發之公告（「該公告」），內容有關其二零二五年年度業績快報公告。 心脈醫療科技為一家於科創板上市之公司。於本公告日期，本公司持有心脈醫療科技已發行股本約 40.32%及其業績於本公司財務報表合併入賬。 於聯交所網站登載該公告，僅為向香港投資者進行同等的資訊傳達及遵守上市規則第13.10B條，別 無其他目的。 承董事會命 中國上海，二零二六年二月二十七日 於本公告日期，本公司之執行董事為常兆華博士；本公司之非執行董事為谷峰博士、門慶兵博士及 孫維琴女士；及本公司之獨立非執行董事為 ...

Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Scientific Corporation (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On February 26, southbound funds increased their holdings by 1.6111 million shares of MicroPort Scientific Corporation [1] - Over the past five trading days, there have been four days of net increases, totaling 2.4247 million shares [1] - In the last 20 trading days, there were 15 days of net increases, amounting to 18.428 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Scientific Corporation, representing 48.28% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business Division, which includes implantable devices and access devices [1] - Orthopedic Medical Devices Business Division, focusing on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM) Business Division, which includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business Division, featuring products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business Division, dealing with cerebral artery atherosclerosis and coils [1] - Structural Heart Disease Business Division, which includes transcatheter aortic valve implantation [1] - Surgical Robotics Business Division, involved in the manufacturing and R&D of surgical robotic devices [1] - Surgical Medical Devices Business Division, focusing on the manufacturing and R&D of surgical medical devices [1]

Core Viewpoint - Southbound funds increased their holdings in MicroPort Scientific Corporation (00853.HK) by 242,100 shares on February 23, indicating a positive sentiment towards the company despite some fluctuations in the previous trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 915,800 shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 15 days, with a cumulative net increase of 16,929,900 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.21% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1] - Key products include implantable devices, surgical robots, and various instruments for cardiovascular and orthopedic applications [1]